Expert Insights on Treatment Selection in Advanced Systemic Mastocytosis

Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.

Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.